Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q4 EPS of ($0.18), $0.06 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.